All Blogs
Nov 15, 2024
CAR-T Cells vs. CAR-Exosome Agents: Exploring the Future of Cancer Immunotherapy
Immunotherapy has revolutionized the treatment landscape for cancer, offering hope for patients who have exhausted traditional therapeutic options. In the ever-evolving field of immunotherapy, two emerging approaches—CAR-T cells and CAR-Exosome agents—are garnering attention for their potential to revolutionize the...
Read More...
Nov 14, 2024
FDA Grants Approval to Caris Life Sciences for MI Cancer Seek; Johnson & Johnson MedTech Secures FDA IDE Approval for OTTAVA; Organogenesis Shares Positive Interim Data from Second Phase 3 Study of ReNu; LivaNova’s OSPREY Trial Achieves Key Safety and Efficacy Milestones; Hyperfine Launches Advanced Portable MR Brain Imaging Swoop® System Across Europe; Nihon Kohden Strengthens Neurological Solutions Through Ad-Tech Medical Instrument Corporation Acquisition
Caris Life Sciences Received FDA Approval for MI Cancer Seek™ as a Companion Diagnostic (CDx) Test On November 6, 2024, Caris Life Sciences, a leading next-generation AI TechBio company and precision medicine pioneer, announced that the U.S. Food and Drug Administration (FDA) approved MI Cancer Seek™ for u...
Read More...
Jun 30, 2025
8 Promising Technologies Powering a More Efficient Operating Room
In today’s healthcare ecosystem, enhancing operating room efficiency is no longer optional—it’s essential. As surgical demand rises and hospital resources are stretched, hospitals are turning to operating room optimization strategies that blend clinical expertise with smart technology. The adoption of operating roo...
Read More...
Nov 12, 2024
AUCATZYL Approved for R/R B-ALL; FDA Accepts NDA for Unicycive’s Oxylanthanum Carbonate; AstraZeneca and Amgen Report Positive Results in Chronic Rhinosinusitis; Nipocalimab Granted Breakthrough Designation for Sjögren’s Disease; AbbVie’s Schizophrenia Drug Fails Phase Studies
FDA Approves Autolus's AUCATZYL for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia Autolus Therapeutics has achieved a significant milestone with FDA approval for AUCATZYL (obecabtagene autoleucel), a next-generation CAR T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic le...
Read More...
Nov 11, 2024
5 Novel CDK7 Inhibitors Pushing the Boundaries in Oncology
In the rapidly evolving field of oncology, novel CDK7 inhibitors are emerging as game-changers, challenging the status quo of cancer treatment. By specifically targeting CDK7, these innovative therapies not only halt cancer cell proliferation but also enhance the effectiveness of existing treatments. With the abili...
Read More...
Nov 08, 2024
ORLYNVAH – The First Oral Penem in the US Market: A New Era in UTI Treatment
Urinary tract infections (UTIs) are among the most prevalent bacterial infections in the US and globally. Around 60% of women will experience an uncomplicated UTI (uUTI) during their lifetime, and up to 40% of women with a history of uUTIs may face a recurrence, according to Iterum’s approval announcement. In 20...
Read More...
Nov 07, 2024
Beta Bionics Introduces iLet Bionic Pancreas with Abbott’s FreeStyle Libre 3 Integration; Merit Medical Successfully Acquires Cook Medical’s Lead Management Portfolio; Elixir Medical’s LithiX HC-IVL System Maintains Safety and Efficacy at Six-Month Mark; Philips Launches U.S. Clinical Trial with First Patient Enrolled for New Integrated Device for PAD; FDA Grants iRhythm Technologies 510(k) Clearance for Enhanced Zio AT Device; SeeMedX Submits 510(k) for Cardiac Monitoring System Aiming to Revolutionize Heart Failure Management
Beta Bionics Launched iLet Bionic Pancreas Along With Abbott’s FreeStyle Libre 3 Plus sensor On October 30, 2024, Beta Bionics, Inc., a leader in developing advanced diabetes management solutions, announced the launch of its iLet Bionic Pancreas and its integration with Abbott’s FreeStyle Libre® 3 Plus sen...
Read More...
Nov 06, 2024
6 Groundbreaking Applications of Organoids That Are Changing Healthcare
The advent of organoid technology has marked a revolutionary milestone in biomedical research and healthcare. Organoids, which are three-dimensional structures derived from stem cells that mimic the architecture and functionality of specific organs, have opened new avenues for understanding diseases, testing drugs,...
Read More...
Nov 05, 2024
Prolong’s PP-007 Fast-Tracked for Stroke; FDA Expands JYLAMVO Pediatric Approval; Corcept’s Cushing’s Drug Shows Positive Phase III Results; ESSA Halts Phase II Study of Masofaniten for Prostate Cancer; SCEMBLIX Approved for Leukemia
Prolong Pharmaceuticals Secures FDA Fast Track for PP-007 in Stroke Therapy Prolong Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company, announced that its investigational therapy, PP-007 (PEGylated carboxyhemoglobin, bovine), has been granted Fast Track designation by the FDA for the treatment of a...
Read More...
Nov 04, 2024
CDK7 Inhibitors: A Promising Class in Cancer Therapeutics
Cyclin-dependent kinase 7 (CDK7) belongs to the CDK family of serine/threonine protein kinases and plays a crucial role in regulating the cell cycle and mRNA transcription. It is often overexpressed in various cancers, making it a promising target for cancer treatment due to its involvement in both transcription an...
Read More...